The FDA is seeking broad legislative changes in its fiscal 2027 budget proposal aimed at accelerating drug development, reducing regulatory burden and expanding oversight authority.
Key proposals outlined in the budget include:
- A new clinical trial notification pathway as an alternative to the investigational new drug process to accelerate early stage trial startup and reduce duplicative requirements. The move aligns with recent FDA efforts to modernize trial design, including January guidance supporting Bayesian methodologies to improve efficiency in complex and small-population studies.
- An abbreviated licensure pathway for biological products to streamline development and increase competition, alongside broader efforts to accelerate innovative therapies such as the agency’s February framework for ultra-rare disease treatments.
- Changes to biosimilar policy, including reducing the need for comparative clinical studies that can take one to three years and cost around $24 million. The proposal builds on October guidance that eliminated routine comparative efficacy study requirements and aimed to expand biosimilar uptake.
- Expanded flexibility for advisory committees, including changes to composition and meeting requirements, part of a broader push to modernize regulatory processes and reduce administrative burden.
- New enforcement authorities targeting unauthorized products across the supply chain, strengthening the agency’s oversight capabilities.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.